Faculty

Institution

Unit

Venue

John P. Fruehauf

Professor of Clinical Medicine

University of California, Irvine

Affiliations

School of Pharmacy and Pharmaceutical Sciences

Department of Pharmaceutical Sciences

John P. Fruehauf is currently serving as a Pharmaceutical Sciences Professor of Clinical Medicine at University of California, Irvine.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

John P. Fruehauf

University of California, Irvine

Professor of Clinical Medicine

You can click a keyword to filter the displayed items

oncology cancer research pharmacology cancer treatment cancer biology medicine gynecologic oncology medicinal research radiation oncology cancer care clinical research ovarian cancer tumor biology gynecology melanoma vascular biology pharmacotherapy cancer management cancer immunotherapy anti-cancer agents angiogenesis tumor targeting breast cancer skin cancer drug resistance enzyme inhibition molecular cancer cellular therapy oncogenes cancer genomics cancer genetics phase ii study in vitro toxicology cancer imaging drug targeting malignant melanoma stage iv melanoma surgical oncology brain tumor research angiology cancer risk radiation biology clinical therapeutics therapeutic efficacy radiation therapy first-line treatment redox biology pharmacological research clinical investigation breast oncology cutaneous biology clinical evidence vascular malformations genitourinary cancers cancer detection cancer growth prognostic biomarkers biomolecular interactions colorectal cancer magnetic resonance imaging advanced melanoma metastatic melanoma early-stage cervical cancer molecular markers cervical carcinoma uterine cervix interim analysis cancer prevention clinical medicine clinical mycology brain imaging multidrug resistance p-glycoprotein expression human melanocytes redox regulation diastolic blood pressure redox mechanisms cell biology anti-cancer agent drug discovery cancer discovery

Notable Scholarly Works

Notable Federal Grants

Collaborators

Southwest Oncology Group S0826: A Phase 2 Trial of Sch 727965 (Nsc 727135, Dinaciclib) in Patients With Stage IV Melanoma. Cancer (2024)

Christopher D. LaoJames MoonVincent T. MaJohn P. FruehaufLawrence E. FlahertyMartin J. BuryWilliam G. MartinHoward GrossWallace AkerleyJudith O. HopkinsSapna P. PatelVernon K. SondakAntoni Ribas

stage iv melanomacancer researchmedicinecancer treatmentclinical trialsoncologycancer biology

Data From Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling. (2023)

Hermann B. FrieboesMary E. EdgertonJohn P. FruehaufFelicity R.A.J. RoseLisa K. WorrallRobert A. GatenbyMauro FerrariVittorio Cristini

drug responsebreast cancerresponse predictionforecastingmedicinal researchpredictive modelingcancer researchdata modelingexperimental medicinedata sciencedrug treatmenthealth sciencesoncologystatistics

Histopathological Analysis of Cerebellum Layersin Rats Treated With Extract of Trichosanthescucumerina: Neuroprotective Functions. Advances in Complementary & Alternative Medicine (2020)

Utibe UdonwaOlaitan R AsuquoJohn P Fruehauf

pathologyneuroprotectionalternative medicinecomplementary medicinehistopathological analysisneuropathologyneuroprotective functionsgeneticscerebellum layersin rats

Open Label, Phase II Study of Axitinib, a Selective Inhibitor of Vascular Endothelial Growth Factor Receptors, in Patients With Stage III Malignant Melanoma.. Journal of Clinical Oncology (2020)

Eric ZhuangJames G. JakowatzMaki YamamotoJohn P. Fruehauf

anti-cancer agentsdrug targetingopen labelpharmacologyphase ii studyvascular biologyselective inhibitorcancer immunotherapycell biologymelanomacancer researchdrug discoverycancer treatmentpharmacotherapyradiation oncologymedicinal researchcancer carevascular pharmacologyclinical researchenzyme inhibitiononcology

Phase II Study of Pazopanib in Combination With Paclitaxel in Patients With Metastatic Melanoma. Cancer Chemotherapy and Pharmacology (2018)

John P. FruehaufMonica El-MasryKatherine OsannBasmina ParmakhtiarMaki YamamotoJames G. Jakowatz

metastatic melanomacancer immunotherapymelanomadermatologyskin cancercancer researchmedicinepharmacologyclinical researchpharmacotherapycancer treatmentclinical therapeuticsoncologyphase ii study

A Phase II Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Patients With Advanced Melanoma.. Journal of Clinical Oncology (2014)

John P. FruehaufBeverly AlgerJames G. JakowatzDavid HsiangLeonard S. SenderClaudette BettisCameron Casey

advanced melanomafirst-line treatmentpharmacologymedicineclinical researchcancer treatmentcancer careoncology

Pharmacokinetics of Single-Agent Axitinib Across Multiple Solid Tumor Types. Cancer Chemotherapy and Pharmacology (2014)

Michael A. TortoriciEzra E. W. CohenYazdi K. PithavalaMay GarrettAna Ruiz-GarciaSinil KimJohn P. Fruehauf

pharmacokineticsmedicinepharmacologysingle-agent axitinibclinical pharmacologypharmacotherapycancer treatmentcancer careoncology

A Phase II Study of Gemcitabine and Oxaliplatin in Advanced Transitional Cell Carcinoma of the Bladder. Cancer Chemotherapy and Pharmacology (2013)

Zeynep ErogluJohn P. Fruehauf

bladder cancercancer treatmentcancer researchmedicinepharmacologyurologypharmacotherapyoncologycancer biologyphase ii study

Updated Interim Analysis of Uci 09-53: A Phase II, Single Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Advanced Melanoma.. Journal of Clinical Oncology (2013)

Shlomit Y. Ein-GalWalter TsangBeverly AlgerBasmina ParmakhtiarJames G. JakowatzClaudette BettisJohn Fruehauf

unresectable advanced melanomasingle arm studyanti-cancer agentsfirst-line treatmentpharmacologycancer immunotherapycancer researchcancer treatmentradiation oncologymedicinal researchmolecular cancercellular therapyphase iiurologycancer carecancer managementclinical trialsinterim analysisclinical researchclinical therapeuticstreatment optionsoncology

A Phase II Single Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Unresectable Stage III and Stage IV Melanoma: Interim Analysis.. Journal of Clinical Oncology (2012)

John P. FruehaufBeverly AlgerBasmina ParmakhtiarJames G. JakowatzClaudette BettisTony ChuangShlomit Y. Ein-Gal

radiation oncologyclinical therapeuticsmedicinal researchmelanomafirst-line treatmentunresectable stage iiistage iv melanomainterim analysiscancer researchpharmacologycancer managementclinical researchcancer treatmentleukemiacancer careoncology

1
2
3
4
5
9
10 / page

John P. Fruehauf

Professor of Clinical Medicine

University of California, Irvine

Affiliations

School of Pharmacy and Pharmaceutical Sciences

Department of Pharmaceutical Sciences

John P. Fruehauf is currently serving as a Pharmaceutical Sciences Professor of Clinical Medicine at University of California, Irvine.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

John P. Fruehauf

University of California, Irvine

Professor of Clinical Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Southwest Oncology Group S0826: A Phase 2 Trial of Sch 727965 (Nsc 727135, Dinaciclib) in Patients With Stage IV Melanoma. Cancer (2024)

Christopher D. LaoJames MoonVincent T. MaJohn P. FruehaufLawrence E. FlahertyMartin J. BuryWilliam G. MartinHoward GrossWallace AkerleyJudith O. HopkinsSapna P. PatelVernon K. SondakAntoni Ribas

stage iv melanomacancer researchmedicinecancer treatmentclinical trialsoncologycancer biology

Data From Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling. (2023)

Hermann B. FrieboesMary E. EdgertonJohn P. FruehaufFelicity R.A.J. RoseLisa K. WorrallRobert A. GatenbyMauro FerrariVittorio Cristini

Histopathological Analysis of Cerebellum Layersin Rats Treated With Extract of Trichosanthescucumerina: Neuroprotective Functions. Advances in Complementary & Alternative Medicine (2020)

Utibe UdonwaOlaitan R AsuquoJohn P Fruehauf

pathologyneuroprotectionalternative medicinecomplementary medicinehistopathological analysisneuropathologyneuroprotective functionsgeneticscerebellum layersin rats

Open Label, Phase II Study of Axitinib, a Selective Inhibitor of Vascular Endothelial Growth Factor Receptors, in Patients With Stage III Malignant Melanoma.. Journal of Clinical Oncology (2020)

Eric ZhuangJames G. JakowatzMaki YamamotoJohn P. Fruehauf

Phase II Study of Pazopanib in Combination With Paclitaxel in Patients With Metastatic Melanoma. Cancer Chemotherapy and Pharmacology (2018)

John P. FruehaufMonica El-MasryKatherine OsannBasmina ParmakhtiarMaki YamamotoJames G. Jakowatz

metastatic melanomacancer immunotherapymelanomadermatologyskin cancercancer researchmedicinepharmacologyclinical researchpharmacotherapycancer treatmentclinical therapeuticsoncologyphase ii study

A Phase II Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Patients With Advanced Melanoma.. Journal of Clinical Oncology (2014)

John P. FruehaufBeverly AlgerJames G. JakowatzDavid HsiangLeonard S. SenderClaudette BettisCameron Casey

advanced melanomafirst-line treatmentpharmacologymedicineclinical researchcancer treatmentcancer careoncology

Pharmacokinetics of Single-Agent Axitinib Across Multiple Solid Tumor Types. Cancer Chemotherapy and Pharmacology (2014)

Michael A. TortoriciEzra E. W. CohenYazdi K. PithavalaMay GarrettAna Ruiz-GarciaSinil KimJohn P. Fruehauf

pharmacokineticsmedicinepharmacologysingle-agent axitinibclinical pharmacologypharmacotherapycancer treatmentcancer careoncology

A Phase II Study of Gemcitabine and Oxaliplatin in Advanced Transitional Cell Carcinoma of the Bladder. Cancer Chemotherapy and Pharmacology (2013)

Zeynep ErogluJohn P. Fruehauf

bladder cancercancer treatmentcancer researchmedicinepharmacologyurologypharmacotherapyoncologycancer biologyphase ii study

Shlomit Y. Ein-GalWalter TsangBeverly AlgerBasmina ParmakhtiarJames G. JakowatzClaudette BettisJohn Fruehauf

A Phase II Single Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Unresectable Stage III and Stage IV Melanoma: Interim Analysis.. Journal of Clinical Oncology (2012)

John P. FruehaufBeverly AlgerBasmina ParmakhtiarJames G. JakowatzClaudette BettisTony ChuangShlomit Y. Ein-Gal

1
2
3
4
5
9
10 / page

Similar Faculty Members

Kenneth Boucher

Institution

University of Utah

cancer letter

biomedical data science

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Jan Hendrik Beumer

Institution

University of Pittsburgh

pharmacology

clinical trial

Ravi K. Amaravadi

Institution

University of Pennsylvania

oncology

cancer research

Frank L. Meyskens

Institution

University of California, Irvine

oncology

cancer research

Alessandro D. Santin

Institution

Yale University

oncology

gynecologic oncology

Peter Schwartz

Institution

Yale University

oncology

gynecologic oncology

Peter J. O'Dwyer

Institution

University of Pennsylvania

oncology

pharmacology

Barbara Burtness

Institution

Yale University

receptor tyrosine kinase

kras inhibition

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Similar Faculty Members

Kenneth Boucher

Institution

University of Utah

cancer letter

biomedical data science

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Jan Hendrik Beumer

Institution

University of Pittsburgh

pharmacology

clinical trial

Ravi K. Amaravadi

Institution

University of Pennsylvania

oncology

cancer research

Frank L. Meyskens

Institution

University of California, Irvine

oncology

cancer research

Alessandro D. Santin

Institution

Yale University

oncology

gynecologic oncology

Peter Schwartz

Institution

Yale University

oncology

gynecologic oncology

Peter J. O'Dwyer

Institution

University of Pennsylvania

oncology

pharmacology

Barbara Burtness

Institution

Yale University

receptor tyrosine kinase

kras inhibition

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine